Skip to content
Home/Companies/Biotech/Code Biotherapeutics
CB

Code Biotherapeutics

Biotech·US·Active·4yr hold

Code Biotherapeutics is a biotech company, headquartered in US.

Entry
2022
Hold
4yr
Status
Active
Est. EV
–

Who owns Code Biotherapeutics?

Code Biotherapeutics is currently owned by 4Bio Partners through 4BIO Ventures III (2022 vintage), since 2022.

Hand-verified · updated 2026-05-21

4Bio Partners
Investor
4Bio Partners
4BIO Ventures III · 2022 · Life Sciences VC

Key facts

HQUS
SectorBiotech
StatusActive

More from 4BIO Ventures III

Other portfolio companies in the same fund.

Cytospire Therapeutics
Active
BiotechUK· 2026
Actithera
Active
BiotechSwitzerland· 2025
Hornet Therapeutics
Active
BiotechUK· 2024
March Biosciences
Active
BiotechUS· 2024
Ascend Advanced Therapies
Active
BiotechUK· 2023
Trogenix
Active
BiotechUK· 2023

More PE-backed in Biotech

Comparable biotech deals from other GPs.

GenSight Biologics
Active
Sofinnova PartnersFrance
InBrain Pharma
Active
Finovam GestionFrance
Isavy Biotech
Active
Ring CapitalFrance
NeoVacs
Active
Odyssée VentureFrance
ReNeuron Group
Exited 2024
Obotritia CapitalUnited Kingdom
Univercells
Exited 2023
AdBio PartnersBelgium
to
Data refreshed weekly · Sourced from public filings